Boston Scientific Corp (BSX)vsPenumbra Inc (PEN)
BSX
Boston Scientific Corp
$69.78
+2.39%
HEALTHCARE · Cap: $101.28B
PEN
Penumbra Inc
$336.27
+0.63%
HEALTHCARE · Cap: $13.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 1330% more annual revenue ($20.07B vs $1.40B). BSX leads profitability with a 14.4% profit margin vs 12.7%. BSX appears more attractively valued with a PEG of 0.75. PEN earns a higher WallStSmart Score of 64/100 (C+).
BSX
Buy63
out of 100
Grade: C+
PEN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+1.2%
Fair Value
$70.62
Current Price
$69.78
$0.84 discount
Margin of Safety
-60.3%
Fair Value
$211.07
Current Price
$336.27
$125.20 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
15.9% revenue growth
Generating 1.0B in free cash flow
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Revenue surging 22.1% year-over-year
Earnings expanding 38.3% YoY
Areas to Watch
Premium valuation, high expectations priced in
Trading at 9.2x book value
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.
Bull Case : PEN
The strongest argument for PEN centers on Altman Z-Score, PEG Ratio, Revenue Growth. Revenue growth of 22.1% demonstrates continued momentum. PEG of 0.76 suggests the stock is reasonably priced for its growth.
Bear Case : BSX
The primary concerns for BSX are P/E Ratio.
Bear Case : PEN
The primary concerns for PEN are Price/Book, P/E Ratio. A P/E of 74.1x leaves little room for execution misses.
Key Dynamics to Monitor
PEN carries more volatility with a beta of 0.84 — expect wider price swings.
PEN is growing revenue faster at 22.1% — sustainability is the question.
BSX generates stronger free cash flow (1.0B), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
PEN scores higher overall (64/100 vs 63/100) and 22.1% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Penumbra Inc
HEALTHCARE · MEDICAL DEVICES · USA
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company is headquartered in Alameda, California.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?